Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice.


Journal

Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230

Informations de publication

Date de publication:
08 2020
Historique:
received: 28 10 2019
revised: 17 02 2020
accepted: 06 04 2020
pubmed: 27 4 2020
medline: 1 7 2021
entrez: 27 4 2020
Statut: ppublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) will soon belong to the top three cancer killers. The only approved specific PDAC therapy targets the epidermal growth factor receptor (EGFR). Although EGFR is a crucial player in PDAC development, EGFR-based therapy is disappointing. In this study, we evaluated the role of the EGFR ligand betacellulin (BTC) in PDAC. The expression of BTC was investigated in human pancreatic cancer specimen. Then, we generated a BTC knockout mouse model by CRISPR/Cas9 technology and a BTC overexpression model. Both models were crossed with the Ptf1a

Identifiants

pubmed: 32335999
doi: 10.1002/1878-0261.12699
pmc: PMC7400790
doi:

Substances chimiques

Betacellulin 0
ErbB Receptors EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1
Receptor, ErbB-4 EC 2.7.10.1
ras Proteins EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1653-1669

Subventions

Organisme : Fritz Thyssen Stiftung
ID : 10.18.1.030MN
Pays : International

Informations de copyright

© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

Références

J Pathol. 2018 Dec;246(4):395-404
pubmed: 30105857
Int J Cancer. 2007 Feb 1;120(3):514-23
pubmed: 17096356
Am J Surg Pathol. 2004 Aug;28(8):977-87
pubmed: 15252303
Mol Cancer Res. 2007 Apr;5(4):309-20
pubmed: 17406026
Mol Oncol. 2015 Nov;9(9):1825-33
pubmed: 26194695
Development. 2007 Mar;134(6):1151-60
pubmed: 17301087
Stem Cells Dev. 2011 Feb;20(2):223-32
pubmed: 20836700
Clin Cancer Res. 2015 Aug 1;21(15):3366-8
pubmed: 25979482
Genes Dev. 2001 Dec 15;15(24):3243-8
pubmed: 11751630
PLoS One. 2008 Aug 06;3(8):e2881
pubmed: 18682844
Exp Cell Res. 2003 Mar 10;284(1):66-77
pubmed: 12648466
Cancer Cell. 2003 Dec;4(6):437-50
pubmed: 14706336
Int J Surg Investig. 2001;2(5):393-400
pubmed: 12678544
Development. 2003 Nov;130(21):5257-68
pubmed: 12954715
Endocrinology. 2005 Dec;146(12):5237-46
pubmed: 16179416
J Gastroenterol. 2020 Mar;55(3):317-329
pubmed: 31456099
FEBS J. 2017 Oct;284(19):3339-3349
pubmed: 28805349
J Clin Invest. 1996 Apr 1;97(7):1647-54
pubmed: 8601630
Anticancer Res. 2018 Dec;38(12):6591-6606
pubmed: 30504367
Gastroenterology. 2009 Sep;137(3):1072-82, 1082.e1-6
pubmed: 19501586
Genesis. 2009 Feb;47(2):85-92
pubmed: 19115345
Diabetes. 2002 Aug;51(8):2505-13
pubmed: 12145164
Exp Cell Res. 2011 Feb 15;317(4):392-404
pubmed: 21110957
Biochem Biophys Res Commun. 2000 Jul 14;273(3):1019-24
pubmed: 10891365
Mech Dev. 2005 Jun;122(6):835-47
pubmed: 15939230
J Clin Invest. 2007 Feb;117(2):337-45
pubmed: 17218988
Oncogene. 2014 Feb 13;33(7):823-31
pubmed: 23376846
Bio Protoc. 2013 Oct 5;3(19):
pubmed: 27453905
Cancer Cell. 2005 May;7(5):469-83
pubmed: 15894267
Diagn Pathol. 2016 Jul 08;11(1):60
pubmed: 27391842
Pharmacol Res. 2014 Jan;79:34-74
pubmed: 24269963
Br J Cancer. 2012 Mar 13;106(6):1033-8
pubmed: 22374460
J Cell Physiol. 2009 Mar;218(3):460-6
pubmed: 19006176
J Clin Oncol. 2007 May 20;25(15):1960-6
pubmed: 17452677
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancers (Basel). 2016 Apr 18;8(4):
pubmed: 27096871
Biochem Biophys Res Commun. 2009 May 8;382(3):561-5
pubmed: 19292977
Trends Biochem Sci. 2014 Feb;39(2):91-100
pubmed: 24388967
Cancer Cell. 2012 Sep 11;22(3):304-17
pubmed: 22975374
J Cell Biol. 2000 Mar 6;148(5):1035-46
pubmed: 10704452
Int J Oncol. 2000 Jan;16(1):37-41
pubmed: 10601546
Gastroenterology. 1998 Nov;115(5):1254-62
pubmed: 9797382
Cancer Cell. 2007 Sep;12(3):266-79
pubmed: 17785207
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Int J Cancer. 1999 Feb 19;84(1):24-7
pubmed: 9988227
Diabetes. 1996 Dec;45(12):1826-31
pubmed: 8922372
Biomed Res Int. 2014;2014:474905
pubmed: 24783207
Int J Oncol. 1995 Oct;7(4):825-9
pubmed: 21552910
Cancer Treat Rev. 2014 Jul;40(6):770-80
pubmed: 24656976
Cell Oncol (Dordr). 2019 Aug;42(4):491-504
pubmed: 31025257
World J Surg Oncol. 2016 Feb 20;14(1):38
pubmed: 26897036
Int J Pancreatol. 2001;29(1):47-52
pubmed: 11558632
Cancer Cell. 2012 Sep 11;22(3):318-30
pubmed: 22975375

Auteurs

Kathrin Hedegger (K)

Institute of Molecular Animal Breeding and Biotechnology, Gene Center of the LMU Munich, Germany.

Hana Algül (H)

Second Department of Internal Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany.

Marina Lesina (M)

Second Department of Internal Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany.

Andreas Blutke (A)

Research Unit Analytical Pathology, Helmholtz Zentrum München, Neuherberg, Germany.

Roland M Schmid (RM)

Second Department of Internal Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany.

Marlon R Schneider (MR)

Institute of Molecular Animal Breeding and Biotechnology, Gene Center of the LMU Munich, Germany.

Maik Dahlhoff (M)

Institute of Molecular Animal Breeding and Biotechnology, Gene Center of the LMU Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH